Eyantra ventures Ltd. (EY) — Tipsheet https://tipsheet.markets/company/ey/ Every Tipsheet Editorial note covering Eyantra ventures Ltd. (EY), newest first. Grounded in BSE/NSE primary-source filings. en-in Mon, 06 Jul 2026 10:22:47 GMT Eyantra's revenue tripled after hospital deal, but full-year profit vanished https://tipsheet.markets/ey-eyantra-s-revenue-tripled-after-hospital-deal-but-full-year-profit-vanished-98110/ https://tipsheet.markets/ey-eyantra-s-revenue-tripled-after-hospital-deal-but-full-year-profit-vanished-98110/ Mon, 25 May 2026 19:44:11 GMT Consolidated top line hit ₹94.2 crore on the back of Neuro and Spine Associates, but the healthcare push cost the group ₹4.75 crore for the full year. Consolidated top line hit ₹94.2 crore on the back of Neuro and Spine Associates, but the healthcare push cost the group ₹4.75 crore for the full year.

What’s new

  • Consolidated revenue surged to ₹94.2 crore as Neuro and Spine Associates added ₹20.5 crore in hospital revenue.
  • Full-year consolidated net loss of ₹4.75 crore, swung by the new healthcare subsidiary.
  • Q4 standalone profit rebounded to ₹6.8 crore; auditor gave an unmodified opinion.

Why it matters

The acquisition of a 60% stake in Neuro and Spine Associates has reshaped Eyantra's financials. The new healthcare segment is driving top-line growth but also absorbing profits, turning a formerly profitable standalone entity into a loss-making consolidated group for the year. Q4's swing back to profit is the first sign that the new business might be stabilising.

What we’re watching

  • Whether Q4's ₹6.8 crore profit carries into FY27.
  • The standalone profit decline from ₹1.66 cr to ₹26.5 lakh.
  • Hospital revenue run-rate post the ₹10.4 crore Q4 surge.

The full read

Eyantra Ventures is now a different company. The acquisition of a 60% stake in Neuro and Spine Associates drove consolidated revenue to ₹94.2 crore, nearly triple the prior year's ₹31 crore. The new hospital services segment alone contributed ₹20.5 crore. But the healthcare push came at a cost: the consolidated group posted a full-year net loss of ₹4.75 crore, a stark reversal from the previously profitable standalone business. Standalone profit fell to ₹26.5 lakh from ₹1.66 crore. There is a silver lining. In the March quarter, consolidated profit swung to ₹6.8 crore on hospital revenue that surged to ₹10.4 crore from ₹3.4 crore in the prior quarter. That's the first full quarter where the new healthcare subsidiary appears to be contributing positively. The auditor's unmodified opinion gives the numbers credibility. The question now is whether Q4's profitability holds.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial Eyantra's revenue tripled. Its new healthcare unit posted a ₹4.75 cr loss. https://tipsheet.markets/ey-eyantra-s-revenue-tripled-its-new-healthcare-unit-posted-a-4-75-cr-loss-98092/ https://tipsheet.markets/ey-eyantra-s-revenue-tripled-its-new-healthcare-unit-posted-a-4-75-cr-loss-98092/ Mon, 25 May 2026 19:35:59 GMT Consolidating a 60% stake in Neuro and Spine Associates flipped the group to a net loss, even as standalone profit fell 84%. Consolidating a 60% stake in Neuro and Spine Associates flipped the group to a net loss, even as standalone profit fell 84%.

What’s new

  • Consolidated revenue nearly tripled to ₹94.2 cr, driven by the consolidation of a 60% stake in Neuro and Spine Associates.
  • The group posted a net loss of ₹4.75 cr, while standalone net profit fell 84% to ₹26.5 lakh.
  • The statutory auditor gave an unmodified opinion on both standalone and consolidated financial statements.

Why it matters

The healthcare acquisition delivered revenue but destroyed profitability. Standalone profit was already falling before consolidation. The clean audit opinion confirms the numbers, but not the wisdom of the deal.

What we’re watching

  • Whether Neuro and Spine Associates can turn profitable to stop dragging the group down.
  • Next quarter's standalone profit trend to gauge core business health.
  • Any further capital allocation to the healthcare vertical.

The full read

Eyantra's growth is an acquisition. Consolidating Neuro and Spine Associates drove group revenue to ₹94.2 crore. It also drove the group to a ₹4.75 crore loss. Standalone, the picture was already deteriorating. Revenue more than doubled to ₹67.5 crore, but profit cratered 84% to ₹26.5 lakh. The margin on that standalone revenue is negligible. The clean auditor's opinion means the numbers are real. The open question is whether the healthcare stake can deliver returns. So far, it has delivered only scale.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial